Abliva Announces Issuance of a New U.S. Patent for Therapeutic Compound NV354

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe mitochondrial diseases, today announced the granting of a composition of matter patent for the NV354 compound by the U.S. Patent and Trademark Office. The patent further strengthens Abliva’s intellectual property position and coverage for the drug candidate NV354, data for which is currently being assembled for clinical trial applications that will facilitate a future Phase 1 start.

On January 31, 2023, the patent “Succinate Prodrug, Compositions Containing the Succinate Prodrug and Uses Thereof” was issued by the U.S. Patent Court as Patent No 11,565,998. The patent covers isolated forms of NV354. This patent provides an important layer of protection for NV354 in addition to previously granted patents for a broader group of NV354-related compounds.

“The granting of this composition of matter patent for NV354 in the U.S. is an important event as it provides additional protection to NV354, which will become increasingly important as we move this compound into clinical development. It also demonstrates our strong commitment to intellectual property at Abliva, ensuring protection of both scientific innovation as well as commercial opportunity for our pipeline of assets”, said Ellen Donnelly, CEO. “Abliva has always had a keen focus on the protection of our assets and the pursuit of robust claims in granted patents across the globe.”